Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 472 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 472 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.29, for a total value of $11,936.88. Following the completion of the transaction, the senior vice president now owns 172,743 shares in the company, valued at $4,368,670.47. This represents a 0.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Stock Performance

Shares of AORT traded down $0.65 during mid-day trading on Thursday, hitting $24.72. 198,675 shares of the company’s stock were exchanged, compared to its average volume of 248,475. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -1,240.75 and a beta of 1.75. The stock’s 50-day simple moving average is $29.32 and its 200-day simple moving average is $27.82. Artivion, Inc. has a 52 week low of $18.56 and a 52 week high of $32.33.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. On average, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

Several large investors have recently made changes to their positions in the company. Quarry LP raised its stake in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after buying an additional 820 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after acquiring an additional 786 shares during the period. R Squared Ltd purchased a new stake in shares of Artivion during the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI purchased a new position in Artivion in the fourth quarter valued at approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion during the fourth quarter valued at $64,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of research reports. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC lowered their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.